Juvaris BioTherapeutics
Juvaris Biotherapeutics, Inc.
About Juvaris BioTherapeutics
Juvaris BioTherapeutics was a biotechnology company founded in 2001 by Jeff Fairman and Martin Cleary.
The company focused on developing adjuvanted vaccines and immunotherapeutics to treat infectious diseases and cancer in both humans and animals. The company is no longer in business.
Jeff Fairman, one of the co-founders, served as the Vice President of Research. His entrepreneurial background and expertise in immunology were instrumental in shaping the company's direction. After Juvaris, Fairman went on to found Vaxcyte, Inc. in 2013, where he continues to serve as Vice President of Research, demonstrating his continued commitment to vaccine development.
Juvaris BioTherapeutics developed a platform technology designed to induce strong and broad-based immune responses. This technology was the cornerstone of their product development efforts, which included a pipeline of immunotherapeutics and adjuvanted vaccines. The company's business model was centered on leveraging this platform to create a portfolio of products for various therapeutic areas. The company operated in the biotechnology and pharmaceutical markets, targeting both human and animal health sectors.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Oct 2010 | $750K | — | Undisclosed | — |
| SERIES BOther financing | Apr 2010 | $13M | $50M | Kleiner Perkins · SV Health Investors | — |
Growth signals
Latest recorded traffic for Juvaris BioTherapeutics is 0 monthly website visits. Juvaris BioTherapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Juvaris BioTherapeutics in the Burlingame ecosystem
The Juvaris BioTherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Kleiner Perkins
SV Health Investors
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Juvaris BioTherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Juvaris BioTherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








